Prospective Evaluation of Visual Outcomes With Tecnis One-Piece Multifocal Intraocular Lenses Compared With Patients Previously Implanted With Crystalens Aspheric Optic (AO)

NCT01191229 | Completed Phase 4

• 1 other identifier: Tecnis One-Piece MF IOL
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

The study is being conducted to collect information about visual outcomes and participant satisfaction with the Tecnis One-Piece Multifocal (MF) Intraocular Lenses (IOLs) compared with participants previously implanted with Crystalens Aspheric Optic (AO) IOLs. The U.S. Food and Drug Administration (FDA) has cleared the Tecnis One-Piece MF IOL for visual correction of aphakia (replacing a removed lens in the eye) in adults.

Conditions

To Collect Information About Visual Outcomes and Participant Satisfaction

Outcome Measures

Primary Outcomes (1)

• Incision size

  Part 1 Only: The primary outcome measure is incision size at three points: Immediately after application of the keratome blade Post phacoemulsification Post Tecnis IOL implantation Target refraction vs. achieved Part 1 and 2: UCVA data at distance, intermediate, and near Near vision will be measured in mesopic and photopic conditions standardized with light meter BCVA at distance and near Enhancement rates Spectacle independence questionnaire and patient satisfaction Incidence of adverse events

  1 year

Study Arms (2)

Tecnis One-Piece MF IOL

NO INTERVENTION

It is planned that about 25 people who are at least 18 years old who are scheduled to have the Tecnis One-Piece Multifocal Intraocular Lenses placed into their eyes after cataract surgery

Device: Tecnis one-piece MF IOL

Crystalens AO

NO INTERVENTION

It is planned that about 25 people who are at least 18 years old and have been implanted with Crystalens AO

Device: Crystalens AO

Interventions

Tecnis one-piece MF IOL DEVICE

25 patients to be implanted after cataract surgery

Tecnis One-Piece MF IOL

Crystalens AO DEVICE

25 patients that are previously implanted

Crystalens AO

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18 or greater
• Bilateral cataracts for which phacoemulsification extraction and posterior IOL implantation has been planned for both eyes
• Visual potential of 20/30 or better in each eye after cataract removal and IOL implantation
• Preoperative best-corrected distance visual acuity (BCDVA) worse than 20/40 Snellen
• Naturally dilated pupil size (in dim light) \> 3.5 mm (with no dilation medications) for both eyes
• Preoperative corneal astigmatism of 1.5 D or less
• Clear intraocular media other than cataract
• Availability, willingness, and sufficient cognitive awareness to comply with examination procedures
• At least 18 years of age
• Underwent bilateral implantation with Crystalens AO at least 6 months previously
• Visual potential of 20/30 or better in each eye after cataract removal and IOL implantation
• Preoperative best-corrected distance visual acuity (BCDVA) worse than 20/40 Snellen
• Naturally dilated pupil size (in dim light) \> 3.5 mm (with no dilation medications) for both eyes
• Preoperative corneal astigmatism of 1.5 D or less
• Clear intraocular media other than cataract

You may not qualify if:

• Use of systemic or ocular medications that may affect vision
• Acute or chronic disease or illness that would increase risk or confound study results (e.g. diabetes mellitus, immunocompromised, etc.)
• Subjects with diabetes mellitus
• Uncontrolled systemic or ocular disease
• History of ocular trauma or prior ocular surgery
• Amblyopia or strabismus
• Known pathology that may affect visual acuity; particularly retinal changes that affect vision (macular degeneration, cystoid macular edema, proliferative diabetic retinopathy, etc.)
• Diagnosed degenerative visual disorders (e.g. macular degeneration, or other retinal disorders) that are predicted to cause future acuity losses to a level of 20/30 or worse
• Patients with forme fruste keratoconus or keratoconus
• Subjects who may be expected to require retinal laser treatment or other surgical intervention
• Capsule or zonular abnormalities that may affect postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome)
• Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or pupils that do not dilate at least 4.0 mm under mesopic/scotopic conditions)
• Contact lens usage within 6 months for PMMA contacts lenses, 1 month for gas permeable lenses or 1 week for extended-wear and daily-wear soft contact lenses
• Requiring an intraocular lens \<15.0 or \>26.0 diopters
• Diagnosed degenerative visual disorders (e.g. macular degeneration, or other retinal disorders) that are predicted to cause future acuity losses to a level of 20/30 or worse

Sponsors & Collaborators

• Innovative Medical: lead

Study Sites (1)

JacksonEye

Lake Villa, Illinois, 60046, United States

Location

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: August 19, 2010
• First Posted: August 30, 2010
• Study Start: July 1, 2010
• Primary Completion: June 1, 2012
• Study Completion: June 1, 2012
• Last Updated: June 14, 2012

Record last verified: 2012-06

Locations

US (1)